IgA-话题@MedSci

#IgA#

129篇内容 | 3272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1503947, encodeId=1f31150394e4a, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=29, createdTime=2020-05-25, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=65, createdTime=2020-05-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503945, encodeId=f60e1503945d5, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, objectType=article, longId=192611, objectId=3a2319261150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2319261150, replyNumber=0, likeNumber=67, createdTime=2020-04-22, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2319261150, moduleTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2319261150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503944, encodeId=3c69150394483, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=IBD：粪便中的IgA水平和肠道菌群组成受NK-T细胞的调节, objectType=article, longId=192148, objectId=213b19214881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=213b19214881, replyNumber=0, likeNumber=53, createdTime=2020-04-14, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=213b19214881, moduleTitle=IBD：粪便中的IgA水平和肠道菌群组成受NK-T细胞的调节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=213b19214881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503943, encodeId=06a81503943b3, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, objectType=article, longId=191608, objectId=8be819160868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8be819160868, replyNumber=0, likeNumber=73, createdTime=2020-04-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8be819160868, moduleTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8be819160868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503942, encodeId=4429150394246, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=肝内胆管癌靶向治疗首次重大突破！Pemigatinib横空出世, objectType=article, longId=189416, objectId=047d18941657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=047d18941657, replyNumber=0, likeNumber=0, createdTime=2020-03-07, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=047d18941657, moduleTitle=肝内胆管癌靶向治疗首次重大突破！Pemigatinib横空出世, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=047d18941657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503941, encodeId=2d841503941a6, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=中药贴膏诱发的线状IgA大疱性皮病1例, objectType=article, longId=189403, objectId=46c418940396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c418940396, replyNumber=0, likeNumber=65, createdTime=2020-03-07, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c418940396, moduleTitle=中药贴膏诱发的线状IgA大疱性皮病1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c418940396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, objectType=article, longId=188104, objectId=396c1881042f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=396c1881042f, replyNumber=0, likeNumber=66, createdTime=2020-02-16, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=396c1881042f, moduleTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=396c1881042f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503939, encodeId=6caf1503939dc, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=69, createdTime=2020-01-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503938, encodeId=221c15039388c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=2019年肾脏病学研究进展系列—IgA肾病, objectType=article, longId=185774, objectId=1d99185e74c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d99185e74c2, replyNumber=0, likeNumber=70, createdTime=2020-01-07, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d99185e74c2, moduleTitle=2019年肾脏病学研究进展系列—IgA肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d99185e74c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Chest：特发性肺纤维化患者瓜氨酸蛋白IgA抗体升高, objectType=article, longId=185418, objectId=0b6418541884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6418541884, replyNumber=0, likeNumber=67, createdTime=2019-12-31, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6418541884, moduleTitle=Chest：特发性肺纤维化患者瓜氨酸蛋白IgA抗体升高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6418541884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503936, encodeId=bcc11503936fe, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, objectType=article, longId=184090, objectId=d0cc1840903e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0cc1840903e, replyNumber=0, likeNumber=63, createdTime=2019-12-05, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0cc1840903e, moduleTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0cc1840903e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503935, encodeId=7cfb15039356f, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, objectType=article, longId=183714, objectId=e945183e14f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e945183e14f6, replyNumber=0, likeNumber=67, createdTime=2019-11-29, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e945183e14f6, moduleTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e945183e14f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503934, encodeId=a8ff1503934ac, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=74, createdTime=2019-11-26, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503933, encodeId=6d03150393367, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=42, createdTime=2019-11-20, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503932, encodeId=bffd150393277, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=67, createdTime=2019-10-23, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503931, encodeId=6eb1150393176, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, objectType=article, longId=178689, objectId=11b21e8689cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11b21e8689cf, replyNumber=0, likeNumber=65, createdTime=2019-09-04, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11b21e8689cf, moduleTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11b21e8689cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503930, encodeId=54d1150393051, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, objectType=article, longId=177009, objectId=bd4e1e700904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd4e1e700904, replyNumber=0, likeNumber=84, createdTime=2019-08-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd4e1e700904, moduleTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd4e1e700904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503929, encodeId=340f15039292a, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Clin Chem：11种血清IgA检测系统检测间一致性的真实性评价与验证, objectType=article, longId=175854, objectId=aa691e5854da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa691e5854da, replyNumber=0, likeNumber=55, createdTime=2019-07-22, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa691e5854da, moduleTitle=Clin Chem：11种血清IgA检测系统检测间一致性的真实性评价与验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa691e5854da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503928, encodeId=3d0b150392899, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病, objectType=article, longId=175551, objectId=4df31e555160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df31e555160, replyNumber=0, likeNumber=58, createdTime=2019-07-17, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df31e555160, moduleTitle=FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4df31e555160)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IgA

2020-05-29

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2020-05-25

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2020-05-08

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA批准胆管癌FGFR靶向药pemigatinib获批

2020-04-22

yibei (审核中...)

前往app查看评论内容

#IgA#

IBD：粪便中的IgA水平和肠道菌群组成受NK-T细胞的调节

2020-04-14

yibei (审核中...)

前往app查看评论内容

#IgA#

Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌

2020-04-08

yibei (审核中...)

前往app查看评论内容

#IgA#

肝内胆管癌靶向治疗首次重大突破！Pemigatinib横空出世

2020-03-07

yibei (审核中...)

前往app查看评论内容

#IgA#

中药贴膏诱发的线状IgA大疱性皮病1例

2020-03-07

yibei (审核中...)

前往app查看评论内容

#IgA#

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

2020-02-16

yibei (审核中...)

前往app查看评论内容

#IgA#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-01-08

yibei (审核中...)

前往app查看评论内容

#IgA#

2019年肾脏病学研究进展系列—IgA肾病

2020-01-07

yibei (审核中...)

前往app查看评论内容

#IgA#

Chest：特发性肺纤维化患者瓜氨酸蛋白IgA抗体升高

2019-12-31

yibei (审核中...)

前往app查看评论内容

#IgA#

成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查

2019-12-05

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌

2019-11-29

yibei (审核中...)

前往app查看评论内容

#IgA#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2019-11-26

yibei (审核中...)

前往app查看评论内容

#IgA#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

yibei (审核中...)

前往app查看评论内容

#IgA#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2019-10-23

yibei (审核中...)

前往app查看评论内容

#IgA#

2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

2019-09-04

yibei (审核中...)

前往app查看评论内容

#IgA#

AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病

2019-08-08

yibei (审核中...)

前往app查看评论内容

#IgA#

Clin Chem：11种血清IgA检测系统检测间一致性的真实性评价与验证

2019-07-22

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病

2019-07-17

科室
- - 订阅+
  - 更多科室
工具
服务